+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Over The Counter Drugs Market - Global Forecast 2026-2032- Product Image
Over The Counter Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Over The Counter Drugs Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4807786
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Over The Counter Drugs Market is projected to reach USD 61.50 Billion in 2026. It is expected to continue growing at a CAGR of 9.03%, reaching USD 103.96 Billion by 2032.

The over-the-counter (OTC) drugs market is a critical pillar of global self-care, enabling consumers to manage common conditions such as pain, fever, allergies, cough and cold symptoms, digestive discomfort, dermatologic issues, and minor infections without a prescription when products are used as directed. Regulatory agencies including the U.S. Food and Drug Administration (FDA), European national competent authorities, and health ministries across Asia-Pacific continue to define OTC availability through safety, labeling, dosage, and pharmacovigilance standards.

Demand is being reinforced by aging populations, higher health awareness, rising out-of-pocket healthcare costs, and the expansion of pharmacy, mass retail, and digital commerce channels. The category is also benefiting from Rx-to-OTC switches, improved labeling, trusted nonprescription medicine brands, and consumer preference for convenient first-line treatment. For industry vendors, growth depends on balancing accessibility with evidence-based safety, transparent claims, supply reliability, and responsible digital engagement.

Transformative Shifts in the OTC Drugs Landscape

The OTC drugs landscape is shifting from product-led retailing to consumer-centered self-care ecosystems. Pharmacies remain trusted access points, but e-commerce, telehealth triage, mobile health applications, and omnichannel fulfillment are changing how consumers discover, compare, and purchase nonprescription medicines. This shift raises the importance of compliant digital content, clear dosage guidance, and search visibility for condition-based queries.

Regulatory modernization is another major force. In the United States, OTC monograph reform under the CARES Act created an administrative order process intended to update standards more efficiently. Globally, regulators are increasing scrutiny of labeling, adverse event reporting, ingredient safety, pediatric use, and claims substantiation. At the same time, inflationary pressure, active pharmaceutical ingredient supply constraints, and private-label competition are pushing manufacturers to strengthen procurement, portfolio segmentation, and brand trust.

Cumulative Impact of Artificial Intelligence on OTC Drugs

Artificial intelligence is becoming a cumulative advantage across the OTC drugs value chain. Manufacturers and retailers are applying AI to demand sensing, inventory planning, search optimization, consumer sentiment analysis, call-center support, and pharmacovigilance signal detection. These capabilities are especially valuable in seasonal categories such as cough, cold, flu, and allergy products, where demand can shift quickly by geography and public health conditions.

AI also supports safer consumer engagement when deployed with validated medical content and regulatory controls. Natural language processing can help monitor adverse event narratives, identify labeling comprehension gaps, and improve product information accessibility. However, AI in OTC drugs must remain governed by human oversight, data privacy safeguards, bias controls, and strict separation between educational support and unauthorized diagnosis or prescribing.

Key Regional Insights for OTC Drugs

Asia-Pacific is one of the most dynamic OTC drugs regions, supported by large populations, expanding middle-income groups, urban pharmacy modernization, and rapid adoption of online health retail. China, India, Japan, South Korea, Australia, and ASEAN markets show different regulatory models, but all are influenced by stronger consumer health awareness, aging demographics in several economies, and growing demand for accessible self-medication across analgesics, gastrointestinal remedies, allergy treatments, dermatology products, and cough, cold, and flu medicines.

North America remains a mature and innovation-driven OTC market, led by the United States and Canada, where established pharmacy chains, mass merchandisers, private labels, pharmacist engagement, and Rx-to-OTC switch pathways shape competition. Latin America is expanding through pharmacy-led access and affordability-focused purchasing, with Brazil and Mexico serving as major demand centers as consumers rely on nonprescription medicines for convenient symptom relief and first-line self-care.

Europe is characterized by high regulatory oversight, pharmacist involvement, and country-specific reimbursement, classification, advertising, and distribution rules that influence OTC product access. The Middle East is benefiting from healthcare infrastructure investment, high retail pharmacy penetration in GCC economies, and growing preference for branded consumer healthcare products. Africa presents long-term potential due to population growth and strong self-care needs, although development is shaped by affordability, distribution reach, counterfeit medicine risks, medicine quality controls, and uneven healthcare access.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as rising urbanization, expanding retail pharmacy networks, and mobile-first consumers increase access to nonprescription medicines across major urban centers and emerging secondary cities. Regulatory harmonization remains gradual, so OTC market entry strategies must account for country-level labeling, registration, import requirements, local language standards, and health authority expectations.

The GCC is attractive for premium OTC brands because of high healthcare spending, modern retail formats, strong pharmacy infrastructure, and government investment in health system modernization. The European Union offers significant regulatory and commercial scale but requires careful navigation of national OTC classifications, pharmacovigilance obligations, language requirements, and advertising rules. BRICS economies combine large populations with expanding self-care adoption and growing domestic pharmaceutical capabilities, although pricing, local manufacturing policy, reimbursement norms, and regulatory complexity vary substantially.

G7 markets remain central for OTC innovation, consumer trust, clinical substantiation, quality standards, and Rx-to-OTC switch activity, supported by established regulatory systems and mature pharmacy channels. NATO countries overlap significantly with North American and European markets, where supply resilience, medicine security, active pharmaceutical ingredient availability, and trusted pharmaceutical distribution have become more strategic after recent global supply disruptions.

Key Country Insights for OTC Drugs

The United States leads global OTC innovation through a large retail base, FDA monograph standards, strong private-label competition, direct-to-consumer education, and continued interest in Rx-to-OTC switches. Canada emphasizes bilingual labeling, pharmacy trust, and safety-focused consumer access, while Mexico and Brazil offer scale in Latin America through high pharmacy utilization, urban retail expansion, and demand for affordable symptom relief.

In Europe, the United Kingdom, Germany, France, Italy, and Spain each maintain distinct OTC classification, advertising, reimbursement, and pharmacy practice norms. Germany and the United Kingdom are notable for established self-care cultures and broad consumer familiarity with pharmacy advice, while France, Italy, and Spain combine pharmacy-centered recommendations with growing digital engagement. Russia remains a sizable nonprescription medicine market, though geopolitical conditions, import constraints, and supply-chain conditions affect multinational participation and product availability.

China and India are pivotal OTC growth markets due to population scale, expanding e-commerce, rising health literacy, and growing self-medication awareness, but companies must manage regulatory localization, price sensitivity, distribution complexity, and local competition. Japan has a sophisticated switched-OTC framework and aging consumers seeking trusted remedies, while Australia maintains strong therapeutic goods regulation and a high level of pharmacy influence. South Korea combines high digital adoption with advanced retail health infrastructure and consumer interest in convenient, technology-enabled healthcare access.

Actionable Recommendations for OTC Drug Industry Leaders

Industry vendors should prioritize evidence-based portfolio expansion in high-demand OTC categories such as analgesics, allergy care, gastrointestinal relief, dermatology, and cough, cold, and flu products. Rx-to-OTC switch opportunities should be evaluated through safety history, consumer label comprehension, misuse risk, dosage clarity, post-market surveillance readiness, and pharmacist support requirements.

Companies should strengthen omnichannel execution by aligning retail availability, e-commerce search performance, compliant product education, and real-time demand planning. Investment in pharmacovigilance, serialization, anti-counterfeit controls, quality assurance, and supplier diversification is essential to protect consumers and defend brand equity. Companies should also develop responsible AI governance, ensuring that personalization and digital assistance improve access without compromising safety, privacy, or regulatory compliance.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. Inputs include regulatory guidance from agencies such as the FDA, European health authorities, and national ministries of health; public health data from organizations such as the World Health Organization and OECD; company disclosures; pharmacy retail trends; and documented developments in OTC monographs, Rx-to-OTC switches, e-commerce, labeling standards, and pharmacovigilance.

Insights are synthesized through qualitative market mapping across OTC product categories, channels, regions, regulatory environments, and consumer behavior drivers. The methodology emphasizes verifiable sources, cross-market comparison, and exclusion of unsupported estimates, sizing, share, or forecasting. Findings are designed to support strategic decision-making for manufacturers, distributors, retailers, investors, and healthcare stakeholders.

Conclusion

The OTC drugs market is advancing from a traditional nonprescription product category into a broader self-care platform shaped by regulation, digital access, AI-enabled operations, and consumer demand for convenient healthcare. Growth opportunities are strongest where organizations combine trusted products, clear labeling, robust safety monitoring, compliant claims, and channel excellence.

Future competitiveness will depend on responsible innovation, regional regulatory fluency, resilient supply chains, and credible consumer education. Organizations that treat OTC medicines as both healthcare products and consumer-facing solutions will be best positioned to support sustainable growth while protecting public health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Over The Counter Drugs Market, by Drug Type
7.1. Introduction
7.2. Cold, Cough, & Allergy Medications
7.2.1. Antihistamines
7.2.2. Cough Suppressants
7.2.3. Decongestants
7.3. Dermatology & Skin Care
7.3.1. Acne Treatments
7.3.2. Antifungal Creams
7.3.3. Skin Protectants
7.4. Digestive Health
7.4.1. Antacids
7.4.2. Anti-diarrheal
7.4.3. Laxatives
7.5. Eye & Ear Care
7.6. Pain Relief Medications
7.7. Vitamins & Supplements
8. Over The Counter Drugs Market, by Product Form
8.1. Introduction
8.2. Capsules
8.3. Liquids/Syrups
8.4. Powders
8.5. Sprays
8.6. Suppositories
8.7. Tablets/Pills
8.8. Topical Creams/Ointments/Gels
9. Over The Counter Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Offline
9.2.1. Pharmacies & Drug Stores
9.2.2. Supermarkets & Hypermarkets
9.3. Online
10. Over The Counter Drugs Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Over The Counter Drugs Market, by End-user
11.1. Introduction
11.2. Healthcare Professionals
11.3. Individual Consumers
11.4. Institutional Users
12. Over The Counter Drugs Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Over The Counter Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Over The Counter Drugs Market, by Country
14.1. United States
14.2. Germany
14.3. China
14.4. United Kingdom
14.5. India
14.6. Japan
14.7. Russia
14.8. Brazil
14.9. Canada
14.10. Italy
14.11. Mexico
14.12. France
14.13. Spain
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amneal Pharmaceuticals LLC
16.2. Aurobindo Pharma Limited
16.3. Bayer AG
16.4. Cipla Limited
16.5. Dr. Reddy’s Laboratories Inc.
16.6. Genomma group
16.7. GSK plc
16.8. Hisamitsu Pharmaceutical Co., Inc.
16.9. Johnson & Johnson Services, Inc.
16.10. LNK International, Inc.
16.11. Novartis AG
16.12. Perrigo Company plc
16.13. Pfizer Inc.
16.14. Pierre Fabre S.A
16.15. PL Developments LLC
16.16. Procter & Gamble Manufacturing Company
16.17. Reckitt Benckiser LLC
16.18. Sanofi S.A.
16.19. Sun Pharmaceutical Industries Limited
16.20. Taisho Pharmaceutical Co., Ltd.
16.21. Teva Pharmaceutical Industries Ltd
16.22. The Mentholatum Company, Inc.
16.23. Tris Pharma, Inc.
16.24. Viatris Inc.
16.25. Wörwag Pharma GmbH & Co. KG
16.26. Zentiva Group, a.s.
List of Figures
FIGURE 1. GLOBAL OVER THE COUNTER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OVER THE COUNTER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OVER THE COUNTER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL COLD, COUGH, & ALLERGY MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL COLD, COUGH, & ALLERGY MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL COLD, COUGH, & ALLERGY MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL COUGH SUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL COUGH SUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL COUGH SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DECONGESTANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DECONGESTANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DECONGESTANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGY & SKIN CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGY & SKIN CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGY & SKIN CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ACNE TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ACNE TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ACNE TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIFUNGAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIFUNGAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIFUNGAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SKIN PROTECTANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SKIN PROTECTANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SKIN PROTECTANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DIGESTIVE HEALTH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL DIGESTIVE HEALTH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL DIGESTIVE HEALTH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ANTACIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-DIARRHEAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-DIARRHEAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-DIARRHEAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL EYE & EAR CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL EYE & EAR CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL EYE & EAR CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PAIN RELIEF MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PAIN RELIEF MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PAIN RELIEF MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL VITAMINS & SUPPLEMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL VITAMINS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL VITAMINS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LIQUIDS/SYRUPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LIQUIDS/SYRUPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LIQUIDS/SYRUPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL POWDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUPPOSITORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SUPPOSITORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SUPPOSITORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TABLETS/PILLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TABLETS/PILLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TABLETS/PILLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TOPICAL CREAMS/OINTMENTS/GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL TOPICAL CREAMS/OINTMENTS/GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TOPICAL CREAMS/OINTMENTS/GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PHARMACIES & DRUG STORES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PHARMACIES & DRUG STORES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PHARMACIES & DRUG STORES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SUPERMARKETS & HYPERMARKETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUPERMARKETS & HYPERMARKETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUPERMARKETS & HYPERMARKETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HEALTHCARE PROFESSIONALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HEALTHCARE PROFESSIONALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HEALTHCARE PROFESSIONALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INDIVIDUAL CONSUMERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INDIVIDUAL CONSUMERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INDIVIDUAL CONSUMERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INSTITUTIONAL USERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INSTITUTIONAL USERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL INSTITUTIONAL USERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 135. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 137. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 138. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 140. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 141. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 144. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 155. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 157. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 158. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 160. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 161. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 162. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 163. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 164. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 168. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 169. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 170. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 171. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 172. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 174. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 176. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 178. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 179. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 180. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 181. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 182. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 184. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 185. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 196. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 198. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 199. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 200. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 201. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 202. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 203. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 204. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 206. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 208. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 209. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 210. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 211. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 212. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 214. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 215. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 216. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 217. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 218. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 219. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 220. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 221. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 222. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 224. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 225. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 226. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 237. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 239. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 240. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 241. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 242. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 243. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 245. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 246. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 247. CHINA OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 249. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 250. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 251. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 252. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 253. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 255. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 256. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 267. INDIA OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 269. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 270. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 271. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 272. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 273. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 274. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 275. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 276. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 277. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 279. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 280. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 281. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 282. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 283. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 284. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 285. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 294. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 295. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 297. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 307. CANADA OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 309. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 310. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 311. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 312. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 313. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 315. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 316. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 317. ITALY OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 319. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 320. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 321. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 322. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 323. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 324. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 325. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 326. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 327. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 329. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 330. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 331. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 332. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 333. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 335. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 336. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 337. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 338. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 339. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 340. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 341. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION)
TABLE 342. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 343. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 344. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 345. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 346. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 347. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 348. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 349. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2017-2032 (USD MILLION)
TABLE 350. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2017-2032 (USD MILLION)
TABLE 351. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2017-2032 (USD MILLION

Companies Mentioned

  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy’s Laboratories Inc.
  • Genomma group
  • GSK plc
  • Hisamitsu Pharmaceutical Co., Inc.
  • Johnson & Johnson Services, Inc.
  • LNK International, Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Pierre Fabre S.A
  • PL Developments LLC
  • Procter & Gamble Manufacturing Company
  • Reckitt Benckiser LLC
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Taisho Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • The Mentholatum Company, Inc.
  • Tris Pharma, Inc.
  • Viatris Inc.
  • Wörwag Pharma GmbH & Co. KG
  • Zentiva Group, a.s.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 61.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 103.96 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

United States Over-The-Counter Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

United States Over-The-Counter Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 100 Pages
  • United States
From
North America OTC Health Products Market Size, Share & Trends Analysis By Application (Digestive Health, Women's Health), Form (Liquid, Gummies), Product, Demography, Distribution Channel, and Segment Forecasts, 2025-2030 - Product Image

North America OTC Health Products Market Size, Share & Trends Analysis By Application (Digestive Health, Women's Health), Form (Liquid, Gummies), Product, Demography, Distribution Channel, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • North America
From
Over the Counter (OTC) Drugs - Global Strategic Business Report - Product Image

Over the Counter (OTC) Drugs - Global Strategic Business Report

  • Report
  • 384 Pages
  • Global
From
Over-The-Counter Consumer Health Products Market - Global Forecast 2026-2032 - Product Image

Over-The-Counter Consumer Health Products Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032 - Product Image

Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From

About the Over the Counter (OTC) Drugs Market

The Over the Counter (OTC) Drugs market is a segment of the pharmaceutical industry that includes drugs that can be purchased without a prescription. These drugs are typically used to treat minor ailments such as headaches, colds, and allergies. OTC drugs are generally considered safe and effective when used as directed. OTC drugs are regulated by the Food and Drug Administration (FDA) and must meet certain safety and efficacy standards. The FDA also requires that OTC drugs be labeled with clear instructions for use. Some of the major players in the OTC Drugs market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Bayer, and Novartis. These companies produce a wide range of OTC drugs, including pain relievers, cold and flu remedies, antacids, and allergy medications. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.